

Title

The findings of Antimicrobial Resistance Surveillance in Bangladesh (2016-2020)

Authors

Zakir Hossain Habib¹, Saima binte Golam Rasul¹, Md. Ashrafal Alam², Nazmun Nahar Bably³, Iqbal Ansary Khan¹, S.M. Shahriar Rizvi⁵, Tahmina Shirin¹, Ahmed Nawsher Alam¹, M. Salim Uzzaman¹, ASM Alamgir¹, Mahbubur Rahman¹, Ashek Ahmmed Shahid Reza¹, Kazi Mohammad Hassan Ameen⁶, AKM Muraduzzaman⁷, Ishrat Siddiqui¹, Zarin Tasnim Haider⁴, Meerjady Sabrina Flora⁸

Affiliations:

¹ Institute of Epidemiology, Disease Control and Research (IEDCR)

² North Bengal Medical College

³ United Nations Children's Fund

⁴ Augmedix BD

⁵ Communicable Disease Control, Directorate General of Health Services (DGHS)

⁶ World Health Organization

⁷ Monash University

⁸ Directorate General of Health Services (DGHS)

Abstract

Antimicrobial resistance is a global problem. Surveillance is one of the effective tools to address this multifaceted problem. In Bangladesh a countrywide antimicrobial resistance surveillance is ongoing since 2016-2020. The main objective of this surveillance is to know the sensitivity pattern of some common bacteria which will eventually help to formulate the guideline for the clinician and to assist the policy makers to know the gravity of the AMR problem in Bangladesh. It is a case based surveillance conducted by Institute of Epidemiology, Disease Control & Research (IEDCR) in nine sentinel sites where five types of clinical cases were selected according to case definition, tested in the microbiology department of the sites and ten types of bacteria were identified from six types of preselected specimens and their sensitivity test were done. All the laboratory works were done following the same standard operative procedure supplied by the AMR surveillance Reference laboratory at IEDCR. Total 19,263 samples were processed during the period of March 2017- March 2020 among which wound swab yielded highest growth (57%). *E.coli* was the highest (1717) isolated organism among the ten priority pathogens which showed highest sensitivity (91%) to Imipenem. Imipenem also showed higher sensitivity to other organisms like *K. pneumoniae* (77%), *Salmonella* species (100%), *P. aeruginosa* (53%) and *Acb complex* (29%). Third generation cephalosporin like ceftriaxone was found less than 50% sensitive to *E.coli* (37%) and *K.pneumoniae* (28%) although *Salmonella* species showed higher sensitivity (97%) to it. *Acb complex*, mostly isolated from ICU patients showed alarming resistance to all of the antibiotics and was less than 50% sensitive to even the highest sensitive antibiotic Imipenem (29%). *Salmonella* species isolated from blood showed higher susceptibility to most of the antibiotics except ciprofloxacin (7%). Alarmingly, only 36%

of the *Staphylococcus aureus* isolates showed susceptibility to ceftazidime indicates high prevalence of MRSA infection.

The result of the surveillance representing whole country is surely alarming as many of the bacteria are resistant to the commonly used as well some of the reserve groups of antibiotics. Concerted effort should be taken from all concerned authorities to curb the problem immediately.

Key words

Surveillance, Antibiotics, Antimicrobial resistance

Introduction

Antimicrobial resistance (AMR) is one of the most complex and multifaceted health challenges facing the global community today. Excessive and inappropriate antibiotic usage is the main cause of the emergence of resistant organisms. Antimicrobial resistance is regarded as the single biggest threat facing the world in the area of infectious diseases. Drug-resistant infections already contribute to at least 700,000 deaths a year (WHO, 2019). In Brazil, Indonesia and Russia, 40 to 60% of infections are already caused by drug-resistant bacteria, compared to an average of 17% in OECD countries (OECD). Given the current trajectory, drug resistance could lead to 10 million deaths annually and plunge 24 million people into extreme poverty by 2050 (WHO, 2019). Left unchecked, AMR is likely to become one of the world's largest health threats, surpassing many other major conditions, such as diabetes and cancer; in scale have a severe effect on economies around the world.

Bangladesh, a developing country of Southeast Asia with a high degree of AMR, poses a regional and global threat. In a study performed in Chittagong in 2003, typhoid patients were found to be unresponsive to second-line therapy (ciprofloxacin). First-line therapy was not even attempted because of existing resistance (Asna et al., 2003). Therapeutic failures like this are not


rare at all. Furthermore, concerning this, multiple studies have demonstrated irrational antibiotic prescribing by physicians, a habit of self-medication among patients, and the indiscriminate use of antibiotics in agriculture and farming in different parts of the country (Shamsuzzaman and Biswas, 2012). Even though many studies have been performed on the prevalence of AMR in Bangladesh, no attempts have yet been made to systematically unify them.

World Health Organization (WHO) acknowledged AMR as a global public health problem in 1998 and urged member states to take measures to encourage appropriate use of antimicrobials. In May 2015, World Health Assembly adopted the Global Action Plan on AMR. All countries are required to develop their national action plan based on the GAP. One of the five strategic objectives of the Global Plan is to strengthen the evidence base through surveillance and research. The World Health Organization (WHO) has developed the Global Antimicrobial Resistance Surveillance System (GLASS) to support the implementation of the Global Action Plan on antimicrobial resistance (AMR). GLASS promotes and supports standardized antimicrobial resistance (AMR) surveillance worldwide.


In concordance with the global and WHO activities on Antimicrobial Resistance Containment (ARC), the Ministry of Health and Family Welfare (MoHFW) in Bangladesh has come forward and the initiative was taken to conduct the program for containment of antimicrobial resistance in Bangladesh. A National Strategy for ARC in Bangladesh as well as National Action Plan 2017-2022 was developed. The establishment of a Surveillance System for AMR is emphasized in (NAP). A nationwide AMR Surveillance in human health is being conducted by the Institute of Epidemiology, Disease Control & Research (IEDCR) since 2016 keeping in line with GLASS as well as country perspective in nine sentinel sites in different geographical locations all over the country to know the status of Antimicrobial resistance pattern of different bacteria.


Materials and Methods

The AMR surveillance in Bangladesh is a ‘case-based surveillance’, one of the three surveillance methods designed under the GLASS protocol. With the technical support from the US-CDC through Global Health Security Agenda (GHSa), World Health Organization (WHO) and Government of Bangladesh, IEDCR conducted the surveillance for the period of March 2016 to March 2020.



Surveillance activities started in 9 sites all over Bangladesh in 2 phases.





Surveillance sites were selected on the basis of geographical representation, ability of the hospital to enroll cases and availability of a nearby microbiology laboratory with capacity to perform culture and sensitivity. Capacity building of the sites included hands-on training (both basic & refresher), providing of laboratory SOPs, providing of instruments, logistics and technical support through the laboratory networking system.

Surveillance activities included collection and testing of samples and compiling of the epidemiological data. The entire laboratory testing including the Antimicrobial Sensitivity Testing (AST), was done at the sentinel sites. Laboratory works have been performed by strictly following the SOPs provided by the AMR Reference Laboratory of IEDCR. All the relevant epidemiological as well as laboratory data were compiled in a software and the hard copy was maintained. The data were cleansed and analyzed using WHONET software at IEDCR.

Internal and external quality control were ensured. For external quality control, a number of positive samples have been retested at the reference laboratory as well as at a third party laboratory. The reference laboratory as well as the sentinel sites participated in Proficiency Testing (PT) by the College of American Pathologists (CAP).

Five different cases of infectious conditions were enrolled from the hospitals by the surveillance physicians following case definitions and specific samples were collected from them according to the protocol which included urine, stool, wound swab, blood, sputum and endotracheal aspirate. In the laboratories, 10 pathogens were identified by biochemical methods from the samples following laboratory SOP and their sensitivity test was done by Kirby-Baur disc diffusion method following CLSI and also, the zone diameter was noted. The organisms identified were-*Escherichia coli*, *Klebsiella pneumoniae*, *Enterococcus spp.*, *Vibrio cholerae*, *Shigella spp.*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Salmonella spp.*, *Pseudomonas aeruginosa* and *Acinetobacter calcoaceticus-baumannii* complex. These 10 pathogens were called the priority pathogens.

Ethical Issue

Patients were selected according to protocol and before taking sample and epi-data informed written as well as verbal consent were taken and other ethical issues are strictly taken into consideration. The protocol was approved by the Institutional Review Board (IRB) of Institute of Epidemiology Disease Control and Research (IEDCR).

Result

Figure: 1 Age & Sex Distribution according to Specimen Type




Figure: 1 demonstrates the age & sex distribution according to specimen type.

Except stool and sputum, the other 4 samples were mostly collected from the patients between the age group of 10-29 years. The highest number of stool samples were collected from the age group 0-9 years and the highest number of sputum samples were collected from the age group 60-69 years. As per the sex distribution, there was no significant difference between male and female patients.

Figure: 2 Distribution of growth in cultured specimen




Figure: 2 demonstrates distribution of growth in cultured specimen

Wound swab yielded the highest growth among the 6 different samples (57%) followed by endotracheal aspirate (48%). On the other hand, stool sample yielded the lowest growth (8%). Here, the growth of *E. coli* in stool sample was not included as the pathogenicity test for the isolates was not done.

Table 1: Distribution of priority pathogens according to specimens

Priority Pathogens	Specimens					
	Wound Swab (n=1717)	Urine (n=1694)	Stool (n=207)	Sputum (n=502)	Endotracheal Aspirate (n=424)	Blood (n=417)
<i>Escherichia coli</i>	233(14%)	1015(60%)	-	51(10%)	35(8%)	65(16%)
<i>Klebsiella pneumoniae</i>	156(9%)	278(16%)	-	231(46%)	149(35%)	31(7%)
<i>Enterococcus</i> species	13(0.76%)	85(5%)	-	2(0.4%)	-	1(0.24%)
<i>Vibrio cholerae</i>	-	-	110(53%)	-	-	-
<i>Shigella</i> species	-	-	47(23%)	-	-	-
<i>Streptococcus pneumoniae</i>	-	-	-	2(0.4%)	1(0.2%)	3(0.7%)
<i>Staphylococcus aureus</i>	235(14%)	115(7%)	2(1%)	95(19%)	26(6%)	36(9%)
<i>Salmonella</i> species	1(0.06%)	-	45(22%)	-	-	243(58%)
<i>Pseudomonas aeruginosa</i>	779(45%)	93(6%)	-	51(4%)	80(19%)	20(5%)
(Acb) Complex	52(3%)	23(1%)	1(0.48%)	10(2%)	108(26%)	12(3%)
Others	248(14%)	85(5%)	2(1%)	60(12%)	25(6%)	6(1%)

Table 1 demonstrates Distribution of priority pathogens according to specimens

Among the 10 priority pathogens, *E. coli* showed the highest growth (60%) in the urine sample.

In the wound swab, *Enterococcus spp.* was the most abundant (76%) followed by *Pseudomonas*

aeruginosa (45%). *Vibrio cholera* was most abundant in stool sample (53%). In the sputum and endotracheal aspirate, *Klebsiella pneumoniae* showed the highest growth (46% and 35% respectively). Acb (*Acinetobacter*) complex was the second highest organism identified from the endotracheal aspirate (26%). In blood, *Salmonella spp.* showed the highest abundance (58%).

Table 2: Antibiotic susceptibility of priority pathogens irrespective of specimens

Antibiotic Name	Priority Pathogens									
	<i>Escherichia coli</i> (n=1417)	<i>Klebsiella pneumoniae</i> (n=845)	<i>Enterococcus species</i> (n=101)	<i>Vibrio cholerae</i> (n=110)	<i>Shigella species</i> (n=47)	<i>Staphylococcus aureus</i> (n=509)	<i>Salmonella spp.</i> (n=244)	<i>Non typhoid-al Salmonella</i> (n=45)	<i>Pseudomonas-aeruginosa</i> (n=1023)	<i>Acb Complex</i> (n=206)
Amikacin	80%	63%	-	-	-	-	98%	-	35%	27%
Amoxicillin-Clavulanate	26%	16%	-	-	-	-	85%	-	-	-
Ampicillin	10%	3%	60%	-	36%	-	74%	26%	-	-
Aztreonam	34%	29%	-	-	-	-	94%	-	20%	-
Azithromycin	-	-	-	83%	53%	12%	-	*	-	-
Ceftazidime	40%	29%	-	-	-	-	98%	-	20%	7%
Clindamycin	-	-	-	-	-	41%	-	-	-	-
Ciprofloxacin	39%	37%	38%	84%	25%	30%	7%	49%	23%	12%
Cephalexin	26%	20%	-	-	-	-	94%	-	-	-
Cefepime	46%	39%	-	-	-	-	98%	-	26%	13%
Ceftriaxone	37%	28%	-	-	89%	-	97%	70%	-	9%
Cefoxitin	-	-	-	-	-	36%	-	-	-	-
Cefuroxime	30%	25%	-	-	-	-	95%	-	-	-

Doxycycline	-	-	-	-	-	66%	-	-	-	27%
Erythromycin	-	-	-	7%	-	-	-	-	-	-
Gentamicin	70%	57%	40%	-	-	63%	98%	-	25%	20%
Imipenem	91%	77%	-	-	-	-	100%	-	53%	29%
Linezolid	-	-	76%	-	-	-	-	-	-	-
Mecillinam	-	-	-	-	64%	-	-	-	-	-
Nitrofurantoin	77%	46%	75%	-	-	-	-	-	-	-
Norfloxacin	45%	49%	-	-	-	-	79%	-	18%	-
Oxacillin	-	-	-	-	-	21%	-	-	-	-
Piperacillin	22%	17%	-	-	-	-	74%	-	30%	6%
Piperacillin-Tazobactam	-	-	-	-	-	-	-	-	38%	20%
Pencillin-G	-	-	38%	-	-	11%	-	-	-	-
Rifampicin	-	-	-	-	-	69%	-	-	-	-
Sulfamethoxazole-Trimethoprim	41%	31%	-	4%	37%	49%	82%	51%	-	21%
Tetracycline	42%	37%	26%	57%	-	-	85%	-	-	-

*Less than 30 isolates tested.

Table 2 demonstrates the antibiotic susceptibility of priority pathogens irrespective of specimen.

A varied range of antibiotic susceptibility is found in different bacteria. Imipenem shows higher sensitivity to different bacteria *Salmonella* showing 100% of it. Ampicillin showed low susceptibility in quite a few pathogens like *E. coli*, *K. pneumoniae* and Non-typhoidal *Salmonella*. *Salmonella* spp. showed high susceptibility to almost all other antibiotics. Among the 10 priority pathogens, *P. aeruginosa* and *Acb complex* showed low sensitivity to almost all the antibiotics. Other than Imipenem, *P. aeruginosa* showed less than 40% sensitivity to other antibiotics and *Acb complex* showed less than 30% sensitivity to all the antibiotics. Only 36%

Staphylococcus aureus isolates showed susceptible to Cefoxitin whereas Clindamycin was sensitive to 41% isolates.

The susceptibility pattern of vancomycin and Linezolid is not mentioned here as the susceptibility tests could not be confirmed by MIC testing.

Table: 3 Antibiogram of Urine

Antibiotic Name	<i>Escherichia coli</i> (n=1015)	<i>Klebsiella pneumoniae</i> (n=278)	<i>Enterococcus</i> species (n=85)	<i>Staphylococcus aureus</i> (n=115)	<i>Pseudomonas aeruginosa</i> (n=93)
Amikacin	86%	82%	-	-	69%
Amoxicillin-Clavulanate	30%	31%	-	-	-
Ampicillin	12%	5%	61%	-	-
Aztreonam	39%	51%	-	-	30%
Azithromycin	-	-	-	7%	-
Ceftazidime	45%	54%	-	-	36%
Clindamycin	-	-	-	45%	-
Ciprofloxacin	44%	57%	41%	41%	40%
Cephalexin	29%	36%	-	-	-
Cefepime	52%	63%	-	-	44%
Ceftriaxone	45%	55%	-	-	-
Cefoxitin	-	-	-	20%	-
Cefuroxime	35%	43%	-	-	-
Doxycycline	-	-	-	70%	-
Gentamicin	78%	75%	46%	75%	63%
Imipenem	95%	92%	-	-	74%
Linezolid	-	-	80%	-	-

Nitrofurantoin	80%	51%	75%	-	-
Norfloxacin	46%	59%	-	-	*
Oxacillin	-	-	-	7%	-
Piperacillin	25%	32%	-	-	53%
Piperacillin-Tazobactam	-	-	-	-	73%
Pencillin-G	-	-	37%	24%	-
Rifampicin	-	-	-	83%	-
Sulfamethoxazole-Trimethoprim	45%	45%	-	53%	-
Tetracycline	45%	49%	26%	-	-

*Less than 30 isolates tested.

Table 3 demonstrates antibiogram of urine sample

Five types of pathogens were identified from the urine sample, where *E. coli* showed the most abundance, followed by *K. pneumoniae*. Imipenem showed the highest sensitivity to the pathogens identified from this sample (above 70%). To both *E. coli* and *K. pneumoniae*, it showed more than 90% sensitivity. Amikacin showed more than 80% sensitivity and Gentamycin showed more than 70% sensitivity to both *E. coli* and *K. pneumoniae*. Ceftriaxone showed only 45% sensitivity to *E. coli*. Ampicillin showed the lowest sensitivity to *E. coli* and *K. pneumoniae* (12% and 5% respectively). Nitrofurantoin showed 80% sensitivity to *E. coli*. The antibiotics showed relatively less sensitivity to *S. aureus* and *P. aeruginosa* pathogens. Cefoxitin and clindamycin were sensitive to 20% and 45% *S. aureus* isolates respectively.

Table: 4 Antibiogram of Wound Swab

Antibiotic Name	<i>Escherichia coli</i> (n=233)	<i>Klebsiella pneumoniae</i> (n=156)	<i>Staphylococcus aureus</i> (n=235)	<i>Pseudomonas aeruginosa</i> (n=779)
Amikacin	59%	40%	-	29%
Amoxicillin-Clavul-anate	8%	6%	-	-
Ampicillin	2%	0%	-	-
Aztreonam	14%	12%	-	18%
Azithromycin	-	-	16%	-
Ceftazidime	26%	9%	-	16%
Clindamycin	-	-	47%	-
Ciprofloxacin	24%	17%	25%	20%
Cephalexin	10%	7%	-	-
Cefepime	29%	18%	-	23%
Ceftriaxone	14%	9%	-	-
Cefoxitin	-	-	50%	-
Cefuroxime	11%	8%	-	-
Doxycycline	-	-	66%	-
Gentamicin	45%	34%	65%	19%
Imipenem	75%	73%	-	51%
Linezolid	-	-	-	-
Norfloxacin	32%	*	-	15%
Oxacillin	-	-	25%	-
Piperacillin	11%	10%	-	28%
Piperacillin-Tazobactam	-	-	-	33%
Pencillin-G	-	-	6%	-
Rifampicin	-	-	76%	-

Sulfamethoxazole-Trimethoprim	27%	17%	54%	-
Tetracycline	20%	27%	-	-

*Less than 30 isolates tested.

Table 4 demonstrates the antibiogram of wound swab sample.

Imipenem showed the highest sensitivity to *E. coli* and *K. pneumoniae* (75% and 73% respectively). Amikacin showed the second highest susceptibility to *E. coli* (59%). Ceftriaxone, showed only 14% and 9% sensitivity to *E. coli* and *K. pneumoniae* respectively. Other than Imipenem, other antibiotics showed less than 35% sensitivity to *P. aeruginosa*. *P. aeruginosa* was the most abundant organism identified from this sample. Rifampicin was found to show the highest sensitivity to *S. aureus* (76%) and the lowest was shown by Penicillin- G (6%). Half of the *S. aureus* isolates were susceptible to ceftiofur and 47% of the isolates showed susceptibility to clindamycin.

Table: 5 Antibiogram of Stool

Antibiotic Name	<i>Vibrio cholerae</i> (n=110)	<i>Shigella</i> species (n=47)	<i>Salmonella</i> species (n=45)
Ampicillin	-	36%	26%
Azithromycin	83%	*	*
Ciprofloxacin	84%	25%	49%
Ceftriaxone	-	89%	70%
Erythromycin	7%	-	-
Mecillinam	-	64%	-
Sulfamethoxazole-Trimethoprim	4%	37%	51%
Tetracycline	57%	-	-

*Less than 30 isolates tested.

Table 5 demonstrates the antibiogram of Stool sample.

Ceftriaxone showed the highest sensitivity to *Shigella* and *Salmonella* species (89% and 70% respectively). Ciprofloxacin showed the highest sensitivity (84%) to *V. cholerae*, followed by Azithromycin (83%), their sensitivity being almost similar.

Table: 6 Antibiogram of Sputum

Antibiotic Name	<i>Klebsiella pneumoniae</i> (n=231)	<i>Staphylococcus aureus</i> (n=95)
Amikacin	80%	-
Amoxicillin-Clavulanate	9%	-
Ampicillin	2%	-
Aztreonam	27%	-
Azithromycin	-	12%
Ceftazidime	25%	-
Clindamycin	-	30%
Ciprofloxacin	43%	30%
Cephalexin	12%	-
Cefepime	44%	-
Ceftriaxone	29%	-
Cefuroxime	21%	-
Doxycycline	-	64%
Gentamicin	72%	65%
Imipenem	86%	-
Norfloxacin	50%	-
Piperacillin	10%	-
Pencillin-G	-	7%
Sulfamethoxazole-Trimethoprim	31%	32%

Tetracycline	35%	-
---------------------	-----	---

Table 6 demonstrates the antibiogram of sputum sample.

Imipenem showed the highest sensitivity to *K. pneumoniae* (86%), followed by Amikacin (80%).

Gentamycin showed the highest sensitivity to *S. aureus*. *S. pneumoniae* was not included in the table as the number of the isolates was less than 30.

Table: 7 Antibiogram of ETA

Antibiotic Name	<i>Klebsiella pneumoniae</i> (n=149)	<i>Pseudomonas aeruginosa</i> (n=80)	(Acb) Complex (n=108)
Amikacin	28%	25%	16%
Amoxicillin-Clavulanate	5%	-	-
Ampicillin	0%	-	-
Aztreonam	3%	10%	-
Ceftazidime	4%	5%	2%
Ciprofloxacin	9%	12%	4%
Cephalexin	0%	-	-
Cefepime	7%	6%	3%
Ceftriaxone	2%	-	4%
Cefuroxime	1%	-	-
Doxycycline	-	-	28%
Gentamicin	24%	13%	7%
Imipenem	37%	25%	15%
Piperacillin	1%	14%	3%
Piperacillin-Tazobactam	-	*	4%
Sulfamethoxazole-Trimethoprim	12%	-	15%

Tetracycline	14%	-	-
---------------------	-----	---	---

*Less than 30 isolates tested.

Table 7 demonstrates the antibiogram of endotracheal aspirate pathogens

Endotracheal aspirate was taken from the ICU patients and all the antibiotics showed low sensitivity to the identified pathogens from this sample (less than 40%). Imipenem showed only 37% sensitivity to *K. pneumoniae*, which was the highest and only 25% sensitivity to *P. aeruginosa*. After Imipenem, Amikacin showed the second highest susceptibility to *K. pneumoniae* and *P. aeruginosa* (28% and 25% respectively). All the antibiotics showed below 20% sensitivity to Acb complex. Cefepime, a Reserve drug, showed less than 10% sensitivity to all the 3 pathogens.

Table: 8 Antibiogram of Blood

Antibiotic Name	<i>Escherichia coli</i> (n=65)	<i>Klebsiella pneumoniae</i> (n=31)	<i>Staphylococcus aureus</i> (n=36)	<i>Salmonella</i> species (n=243)
Amikacin	74%	50%	-	98%
Amoxicillin-Clavulanate	27%	*	-	85%
Ampicillin	9%	*	-	74%
Aztreonam	24%	*	-	94%
Azithromycin	-	-	13%	-
Ceftazidime	30%	33%	-	98%
Clindamycin	-	-	35%	-
Ciprofloxacin	32%	27%	42%	7%
Cephalexin	17%	*	*	94%
Cefepime	32%	*	-	98%

Ceftriaxone	18%	*	-	97%
Cefuroxime	19%	*	-	95%
Doxycycline	-	-	80%	-
Gentamicin	63%	*	57%	98%
Imipenem	89%	*	-	100%
Norfloxacin	15%	*	-	82%
Piperacillin	14%	*	-	74%
Sulfamethoxazole-Trimethoprim	25%	23%	*	82%
Tetracycline	46%	*	-	86%

*Less than 30 isolates tested.

Table 8 demonstrates the antibiogram of blood sample.

Among the identified pathogens from the blood sample, *Salmonella* was found to be the most abundant. Other than *Salmonella* and *E. coli*, the growth of other pathogens in blood was poor. Almost all the antibiotics showed above 70% sensitivity to *Salmonella* species other than Ciprofloxacin, which showed only 7% sensitivity. Imipenem was found to be 100% sensitive to *Salmonella*. Imipenem also showed the highest sensitivity to *E. coli* (89%). Doxycycline showed the highest sensitivity to *S. aureus* (80%). Amikacin showed above 50% sensitivity to the identified pathogens.

Discussion

Like other LMICs, Bangladesh is also facing the problem of AMR and the extent of this AMR is not clear due to the lack of adequate data. The AMR surveillance in Bangladesh 2016-2020 is the first of its kind including all geographical areas in Bangladesh to find out the resistance pattern of ten important bacterial pathogens from six types of samples collected from patients attending outdoors and indoors presented with five clinical syndromes.

Total 19,263 samples were processed. Other than stool and sputum, most of the samples were collected from the age group of 10-29 years. Stool sample was mostly taken from the pediatric department (the age group was between 0 and 9 years). Some of the stool samples were also collected from the Infectious Disease Hospital and ORT unit of Medical college hospitals. Sputum was mostly collected from the age group of 60-69 years. The male and female distribution showed no significant variation in terms of collection of samples.

Even though among the collected samples, urine was the highest in number, it yielded only 19% growth. A study done in a tertiary hospital in Bangladesh from outdoor and indoor sample it yielded similar result where 20.1% showed significant growth of bacteria (Afroze et.al, 2019).

The lowest growth in culture was yielded by stool (9%). This may be due to exclusion of growth of *E. coli* as its pathogenicity test could not be done. Wound swab and ETA yielded the highest growth, the percentage being 57% and 48% respectively.

Among the gram negative pathogens, *E. coli* showed the highest (28%) growth followed by *Pseudomonas aeruginosa* (21%), *Klebsiella pneumonia* (13%), *Salmonella* species (6%), *Acinetobacter baumannii* (ACB) complex (4%), *Vibrio cholera* (2%) and *Shigella* species (1%).

E.coli yielded highest growth (60%) in urine which is in line with other studies like one conducted in a tertiary care hospital in Bangladesh where *E. coli* (58.18%) was the most

prevalent bacteria isolated from positive urine samples' (Biswas et al., 2014) and also *E. coli* showed mostly resistant to penicillins and cephalosporins. Fluoroquinolones and other protein synthesis inhibitors also showed less susceptibility pattern. In UTI, nitrofurantoin is the only oral drug showed better (80%) susceptibility profile. Imipenem showed the most effective (95%) against *E. coli* followed by Amikacin (86%). *E. coli* isolated from the wound swab showed most resistant profile than other samples. In Indian surveillance system, they found colistin, imipenem, meropenem, amikacin and gentamycin as effective drugs which has a concordance with the present study (Veeraraghavan and Walia, 2019). They also found combination like piperacillin-tazobactam and ceftazidime-sulbactam as effective drugs, which could not be evaluated in our setup. The Indian studies found ESBL producing *E. coli* were the responsible for such resistance pattern for penicillin and cephalosporin (Bora et al., 2014, Ranjan et al., 2016).

Pseudomonas species showed the second highest growth following *E. coli*. It is the highest isolated pathogen in wound swab (45%). The samples were collected mainly from the surgery ward followed by burn unit and medicine unit. A study in Nigeria showed similar result where *Pseudomonas aeruginosa* was highest (33.3%) isolated pathogen in post-operative patients followed by *Staphylococcus aureus* (21.7%) (Oguntibeju and Rau, 2004). While a tertiary care hospital in Nepal, pus and wound swab samples from paediatric patients *S. aureus* was the highest isolated organism followed by *P. aeruginosa* (Rai et al., 2017).

The overall susceptibility pattern of *Pseudomonas* showed very poor profile. *Pseudomonas* were highest susceptible (53%) to Imipenem followed by Piperacillin-Tazobactam (38%) and Amikacin (35%). Only Piperacillin showed 38% sensitivity to *Pseudomonas*. All other antibiotic showed sensitivity below 30%. Isolates of *Pseudomonas aeruginosa* from ETA were the most resistant. Studies across India showed better susceptibility patterns with colistin followed by

aminoglycosides (amikacin/ gentamycin), piperacillin/tazobactam, cephalosporins, fluoroquinolones and carbapenems (imipenem/ meropenem) (Ahmed and Hussain, 2014, Rose et al., 2015, Veeraraghavan and Walia, 2019). *Pseudomonas aeruginosa* has already been prioritized for its multidrug resistance nature (Frieden, 2013).

Klebsiella pneumoniae mostly grew from sputum (46%) and ETA (35%). A study done at Nigeria also found *K. pneumoniae* as the highest isolated pathogen followed by *H. influenzae* and then *Staph. aureus* (Egbe et al., 2011). Another study done in a tertiary care hospital, Bali, Indonesia found *K. pneumoniae* the highest isolated pathogen followed by *Acinetobacter baumannii* (Budayanti et al., 2019).

In this study ETA was cultured from ventilated patient's sample at ICU and *K. pneumoniae* was found to be the highest pathogen followed by *Acinetobacter complex*. Most of the bacteria isolated were gram negative bacilli (86%). Among the gram positive bacteria, *S. aureus* was the highest one (6%). A prospective study done in a tertiary care hospital in Pondicherry, India showed similar result most cases of VAP were caused by Gram negative bacteria, which accounted for 80.9% of the causative organisms. *Acinetobacter baumannii* (23.4%) and *Pseudomonas aeruginosa* (21.3%) were the predominant Gram-negative bacteria associated with VAP, and *Staphylococcus aureus* (14.9%) was the most common Gram-positive bacterium among patients with VAP (Joseph et al., 2010)

The overall susceptibility pattern showed below 50% for most of the antibiotics except Imipenem (77%), Amikacin (63%) and gentamicin (57%). Isolates from ETA showed the most resistant profile than others. Susceptibility showed diversity in India with high rates of ESBL producing. Susceptibility to carbapenems showed diverse range from 44 to 72%, amikacin

showed 65% while gentamicin susceptibility was 55% (Gandra et al., 2016, Veeraraghavan et al., 2017).

More than half (58%) of the isolates from blood were *Salmonella* species. Isolates from blood showed excellent sensitivity pattern except ciprofloxacin (7%) and ampicillin (74%). In India, *Salmonella enterica serovar Typhi* and *Paratyphi* was predominant blood isolates. In *S. Typhi* and *paratyphi*, they found nalidixic acid as the most resistant drug with a variable finding of ciprofloxacin (0-81%). Other drugs had better susceptibility pattern. Stool constituted 20% by *Salmonella* species. Isolates from stool samples here showed very different scenario with a highest sensitivity (70%) to ceftriaxone assuming that they might be non typhoidal salmonellosis (NTS). Among NTS from India, susceptibility was observed for ampicillin (0-93%), cotrimoxazole (42-93%), chloramphenicol (45-100%), nalidixic acid (23-76%), ciprofloxacin (9-100%), ceftriaxone and azithromycin (>90%) (Dahiya et al., 2017, Dutta et al., 2014, Rudresh and Nagarathnamma, 2015, Taneja et al., 2014). *Shigella* species from stools have also similar sensitivity pattern whereas

V. Cholera was the most abundant bacteria (48%) in stool. Two of the major causes of severe diarrhea in low-resource countries, are the bacterial pathogens *Vibrio cholerae* (O1), which causes epidemic cholera, and enterotoxigenic *Escherichia coli* (ETEC) (Begum et al., 2018). We excluded *E. coli* as there is lack of capacity to toxigenicity in our laboratory set up.

In a systemic surveillance on diarrheal patients carried out by icddr, b, it was found that the most prevalent pathogen isolated was *Vibrio cholerae* O1 (23%) followed by ETEC (11%) (Chowdhury et al., 2011)

Vibrio cholerae had good susceptibility patterns to ciprofloxacin and azithromycin. In India, the antimicrobial susceptibility profile observed were, ampicillin (0-68%), trimethoprim-

sulphamethoxazole (0-33%), chloramphenicol (30-90%), tetracycline (2-70%), nalidixic acid (0-66%), ciprofloxacin (10-94%), norfloxacin (14-94%), ofloxacin (6-90%) and cefixime (0-95%) (Aggarwal et al., 2014, Anandan et al., 2017, Das et al., 2016).

Though *Acinetobacter baumannii* (ACB) complex comprises only 4% of total, it constituted 26% of ETA isolates. Susceptibility profile is worst as expected showed most sensitive to Imipenem by 29%. But studies from India got better susceptibility patterns for imipenem, meropenem, amikacin, tobramycin, netilmicin and colistin compared to our surveillance reports (Pragasam et al., 2017, Shrivastava et al., 2013, Tripathi et al., 2014).

Among the gram positive organisms, *Staphylococcus aureus* was the most (10%) prevalent followed by *Enterococcus* species and *Streptococcus pneumoniae*. *Staphylococcus aureus* isolates were mostly found in respiratory samples followed by wound swab, blood and urine. The overall susceptibility pattern showed the most effective drug was Rifampicin (69%) and the least was Penicillin-G (11%). Only 36% isolates showed sensitivity towards Cefoxitin indicates the high MRSA burden in the region. It still needs to differentiate the healthcare associated and community acquired infections to identify the actual magnitude of the MRSA in these settings. We could not evaluate the source of the infection either hospital origin or community origin. The overall clindamycin susceptibility was higher (41%) than the cefoxitin albeit we could not evaluate the clinical significance of this findings due to lack of performing the inducible clindamycin resistance test in our sentinel sites. In India, *S. aureus* (MSSA) and methicillin-resistant *S. aureus* (MRSA) is reported separately. They found almost 40% isolates as MRSA. For MRSA, poor susceptibility to gentamicin (28-44%), erythromycin (9-69%), clindamycin (35-71%), co-trimoxazole (27-66%) and ciprofloxacin (8-21%) was found (India et al., 2013, Moolchandani et al., 2017, Rajkumar et al., 2017)

Enterococcus isolates were mostly present in the Urine. The most sensitive drug was Nitrofurantoin to be found effective against *Enterococcus*. Susceptibility pattern in Indian studies were ampicillin (3-35%), gentamicin (16-89%), vancomycin (77-100%) and linezolid (98-100%).

Vancomycin resistance was reported around 20% (Praharaj et al., 2013, Sachan et al., 2017, Singh et al., 2014). Only 06 *Streptococcus pneumoniae* could be isolated from respiratory samples and blood. The fastidious nature of this organism could be underestimated the actual. Very few isolates are not conclusive to evaluate the antibiogram as it is below 30 in number.

Limitations of the study

As the participatory laboratories were not capable of performing MIC testing, some of the important resistant pattern could not be confirmed which required it according to CLSI. Furthermore, toxigenicity test of stool samples yielding *E.coli* could not be performed so that one of the important diarrheagenic pathogen had to exclude from the susceptibility list.

Conclusion

AMR Surveillance is an essential tool for getting necessary information to develop and monitor therapy guidelines, antibiotic stewardship programmes, public health interventions and infection control policies. It enables early detection of resistant strains of public health importance, and supports the prompt notification and investigation of outbreaks and ultimately guides to policy recommendations.

Running a standard and reliable surveillance is extremely important as well as challenging especially in resource poor country like Bangladesh. The ongoing AMR surveillance program, with all its limitations and challenges is unique for its countrywide expansion and coordinated

approach of hospital physicians, nurses of medical college hospitals and laboratory personnel of microbiology departments of the medical colleges. The susceptibility pattern of different microorganisms as revealed by the surveillance is indeed alarming. Except Imipenem most of the commonly used antibiotics showed ineffective for most of the bacteria. ACB complex, most of which organism has been found from ICU patient's specimen showed less than 50% sensitivity to all of the used antibiotics. *Vibrio cholerae* isolated from stool samples showed similar sensitivity to ciprofloxacin (84%) and azithromycin (83%) whereas *Shigella* spp. showed only 53% sensitivity to azithromycin while ceftriaxone (89%) showed highest sensitivity. *Salmonella* spp. from blood showed high sensitivity (70-100%) to most of the antibiotics except ciprofloxacin (7%). *Staph. aureus* is only 36% sensitive to ceftiofur which indicates the possibility to a very high number of MRSA. Antibiotics like ampicillin, sulphamethoxazole-trimethoprim and tetracycline which was previously used commonly does not seem to be effective to most of the bacteria except salmonella spp. It is high time all relevant stakeholders should come forward to curb the upcoming threat.

Acknowledgement

We acknowledge all the staffs of National Reference Laboratory of AMR, IEDCR, Bangladesh and staffs of the sentinel sites for their intense support for this study. The AMR surveillance is funded by the Government of Peoples Republic of Bangladesh, World Health Organizations and Centers for Disease Control and Prevention, USA.

References

Afroze S., Habib Z.H., Billah, S.M.B., Akhter H., Jahan H., Parveen R. 2019. Spectrum and Antibiotic Resistance Pattern of Bacteria Causing Urinary Tract Infections (UTI) in a Tertiary Care Hospital. *Journal of Surgical Sciences* 23, 13-18.

Aggarwal, P., Uppal, B., Ghosh, R., Jha, A. K. & Konar, D. 2014. Surveillance of changing antimicrobial resistance pattern in *Shigella* in North India. *Int J*, 2, 166-71.

Ahmed, N. H. & Hussain, T. 2014. Antimicrobial susceptibility patterns of leading bacterial pathogens isolated from laboratory confirmed blood stream infections in a multi-specialty sanatorium. *Journal of global infectious diseases*, 6, 141.

Anandan, S., Sethuvel, D. P. M., Gajendiren, R., Verghese, V. P., Walia, K. & Veeraraghavan, B. 2017. Molecular characterization of antimicrobial resistance in clinical *Shigella* isolates during 2014 and 2015: trends in South India. *Germs*, 7, 115.

Asna, S., Haq, J. A. & Rahman, M. M. 2003. Nalidixic acid-resistant *Salmonella enterica* serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. *Japanese journal of infectious diseases*, 56, 32-33.

Begum, Y. A., Rydberg, H. A., Thorell, K., Kwak, Y.-K., Sun, L., Joffré, E., Qadri, F. & Sjöling, Å. 2018. In situ analyses directly in diarrheal stool reveal large variations in bacterial load and active toxin expression of enterotoxigenic *Escherichia coli* and *Vibrio cholerae*. *Msphere*, 3.

Biswas, R., Rabbani, R., Ahmed, H. S., Sarker, M. A. S., Zafrin, N. & Rahman, M. M. 2014. Antibiotic sensitivity pattern of urinary tract infection at a tertiary care hospital. *Bangladesh Critical Care Journal*, 2, 21-24.

Bora, A., Hazarika, N. K., Shukla, S. K., Prasad, K. N., Sarma, J. B. & Ahmed, G. 2014. Prevalence of blaTEM, blaSHV and blaCTX-M genes in clinical isolates of Escherichia coli and Klebsiella pneumoniae from Northeast India. Indian journal of Pathology and Microbiology, 57, 249.

Budayanti, N. S., Suryawan, K., Iswari, I. S. & Sukrama, D. M. 2019. The quality of sputum specimens as a predictor of isolated bacteria from patients with lower respiratory tract infections at a tertiary referral hospital, Denpasar, Bali-Indonesia. Frontiers in medicine, 6, 64.

Chowdhury, F., Rahman, M. A., Begum, Y. A., Khan, A. I., Faruque, A. S., Saha, N. C., Baby, N. I., Malek, M., Kumar, A. R. & Svennerholm, A.-M. 2011. Impact of rapid urbanization on the rates of infection by Vibrio cholerae O1 and enterotoxigenic Escherichia coli in Dhaka, Bangladesh. PLoS Negl Trop Dis, 5, e999.

Dahiya, S., Sharma, P., Kumari, B., Pandey, S., Malik, R., Manral, N., Veeraraghavan, B., Pragasam, A. K., Ray, P. & Gautam, V. 2017. Characterisation of antimicrobial resistance in Salmonellae during 2014–2015 from four centres across India: An ICMR antimicrobial resistance surveillance network report. Indian journal of medical microbiology, 35, 61-68.

Das, A., Natarajan, M. & Mandal, J. 2016. The emergence of quinolone resistant Shigella sonnei, Pondicherry, India. PLoS One, 11, e0160290.

Dutta, S., Das, S., Mitra, U., Jain, P., Roy, I., Ganguly, S. S., Ray, U., Dutta, P. & Paul, D. K. 2014. Antimicrobial resistance, virulence profiles and molecular subtypes of Salmonella enterica serovars Typhi and Paratyphi A blood isolates from Kolkata, India during 2009-2013. PloS one, 9, e101347.

Egbe, C. A., Ndiokwere, C. & Omoregie, R. 2011. Microbiology of lower respiratory tract infections in Benin City, Nigeria. *The Malaysian journal of medical sciences: MJMS*, 18, 27.

Frieden, T. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, US Department of Health and Human Services, 23, 11-28.

Gandra, S., Mojica, N., Klein, E. Y., Ashok, A., Nerurkar, V., Kumari, M., Ramesh, U., Dey, S., Vadwai, V. & Das, B. R. 2016. Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008–2014. *International Journal of Infectious Diseases*, 50, 75-82.

India, S. J., Ray, P., Manchanda, V., Bajaj, J., Chitnis, D., Gautam, V., Goswami, P., Gupta, V., Harish, B. & Kagal, A. 2013. Methicillin resistant *Staphylococcus aureus* (MRSA) in India: prevalence & susceptibility pattern. *The Indian journal of medical research*, 137, 363.

Joseph N.M., Sistla S., Dutta T.K., Badhe A.S., Rasitha D., Parija S.C. 2010. Ventilator-associated pneumonia in a tertiary care hospital in India: role of multi-drug resistant pathogens. *J Infect Dev Ctries*. 4, 218-225.

Moolchandani, K., Sastry, A. S., Deepashree, R., Sistla, S., Harish, B. & Mandal, J. 2017. Antimicrobial resistance surveillance among intensive care units of a tertiary care hospital in Southern India. *Journal of clinical and diagnostic research: JCDR*, 11, DC01.

OECD. Stopping antimicrobial resistance would cost just USD 2 per person a year [Online]. Available: <https://www.oecd.org/newsroom/stopping-antimicrobial-resistance-would-cost-just-usd-2-per-person-a-year.htm> [Accessed 14 February 2021].

Oguntibeju, O. & Rau, N. 2004. Occurrence of *Pseudomonas aeruginosa* in post-operative wound infection. *Pakistan Journal of Medical Sciences*, 20, 187-192.

Pragasam, A., Vijayakumar, S., Bakthavatchalam, Y., Kapil, A., Das, B., Ray, P., Gautam, V., Sistla, S., Parija, S. & Walia, K. 2017. Molecular characterisation of antimicrobial resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* during 2014 and 2015 collected across India. *Indian journal of medical microbiology*, 34, 433-441.

Praharaj, I., Sujatha, S. & Parija, S. C. 2013. Phenotypic & genotypic characterization of vancomycin resistant *Enterococcus* isolates from clinical specimens. *The Indian journal of medical research*, 138, 549.

Rai, S., Yadav, U. N., Pant, N. D., Yakha, J. K., Tripathi, P. P., Poudel, A. & Lekhak, B. 2017. Bacteriological profile and antimicrobial susceptibility patterns of bacteria isolated from pus/wound swab samples from children attending a tertiary care hospital in Kathmandu, Nepal. *International journal of microbiology*, 2017.

Rajkumar, S., Sistla, S., Manoharan, M., Sugumar, M., Nagasundaram, N., Parija, S. C., Ray, P., Bakthavatchalam, Y. D., Veeraraghavan, B. & Kapil, A. 2017. Prevalence and genetic mechanisms of antimicrobial resistance in *Staphylococcus* species: A multicentre report of the Indian council of medical research antimicrobial resistance surveillance network. *Indian journal of medical microbiology*, 35, 53-60.

Ranjan, A., Shaik, S., Mondal, A., Nandanwar, N., Hussain, A., Semmler, T., Kumar, N., Tiwari, S. K., Jadhav, S. & Wieler, L. H. 2016. Molecular epidemiology and genome dynamics of New Delhi metallo- β -lactamase-producing extraintestinal pathogenic *Escherichia coli* strains from India. *Antimicrobial agents and chemotherapy*, 60, 6795-6805.

Rose, W., Veeraraghavan, B. & George, B. 2015. Bloodstream infections in children with febrile neutropenia: Isolates and their antimicrobial susceptibility profile. *Indian journal of cancer*, 52, 495.

Rudresh, S. M. & Nagarathnamma, T. 2015. Antibiotic susceptibility pattern of *Salmonella enterica* serovar typhi and *Salmonella enterica* serovar paratyphi A with special reference to quinolone resistance. *Drug Development & Therapeutics*, 6.

Sachan, S., Rawat, V., Umesh, M. K., Kaur, T. & Chaturvedi, P. 2017. Susceptibility pattern of enterococci at tertiary care hospital. *Journal of global infectious diseases*, 9, 73.

Shamsuzzaman, M. M. & Biswas, T. K. 2012. Aqua chemicals in shrimp farm: A study from south-west coast of Bangladesh. *The Egyptian Journal of Aquatic Research*, 38, 275-285.

Shrivastava, G., Bhatambare, G. S., Bajpai, T. & Patel, K. B. 2013. Sensitivity profile of multidrug resistant *Acinetobacter* Spp. isolated at ICUs of tertiary care hospital. *International Journal of Health System and Disaster Management*, 1, 200.

Singh, A. K., Venkatesh, V., Singh, R. P. & Singh, M. 2014. Bacterial and antimicrobial resistance profile of bloodstream infections: a hospital-based study. *CHRISMED Journal of Health and Research*, 1, 140.

Taneja, N., Appannanavar, S. B., Kumar, A., Varma, G., Kumar, Y., Mohan, B. & Sharma, M. 2014. Serotype profile and molecular characterization of antimicrobial resistance in non-typhoidal *Salmonella* isolated from gastroenteritis cases over nine years. *Journal of medical microbiology*, 63, 66-73.

Tripathi, P. C., Gajbhiye, S. R. & Agrawal, G. N. 2014. Clinical and antimicrobial profile of *Acinetobacter* spp.: An emerging nosocomial superbug. *Advanced biomedical research*, 3.

Veeraraghavan, B. & Walia, K. 2019. Antimicrobial susceptibility profile & resistance mechanisms of Global Antimicrobial Resistance Surveillance System (GLASS) priority pathogens from India. *The Indian journal of medical research*, 149, 87.

Veeraraghavan, B., Shankar, C., Karunasree, S., Kumari, S., Ravi, R. & Ralph, R. 2017. Carbapenem resistant *Klebsiella pneumoniae* isolated from bloodstream infection: Indian experience. *Pathogens and global health*, 111, 240-246.

WHO, 2019. New report calls for urgent action to avert antimicrobial resistance crisis. World Health Organization website. <https://www.who.int/news-room/detail/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis>. Accessed April, 4.